Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Therapeutic in situ CAR T cells in genetically humanized HLA DQ8 mouse models 4607
Pease, Larry R. , Hansen, Michael, Keulen, Virginia P. Van , Peña, Alvaro, Parks, Christopher R., Guttormson, Matthew R., Jenkins, James W. , Hinson, Destin T , Powell, Noah J., Felts, Sara J. , Johnson, Aaron R. , Parks, Christopher R., Guttormson, Matthew C. , Powell, Noah J., Taneja, Veena , Mangalam, Ashutosh K. , Barry, Michael A.

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.2267 Get It

Abstract Description Antigen receptor (CAR) T cells can be generated in vivo within the natural lymph node (LN) environment as the immune response to a virus infection unfolds. This in situ approach entails priming LNs with intradermal inoculations of replication defective adenoviruses encoding MHC class I and class II allo/xeno-antigens. Universal transplant antigens were devised for LN priming by introducing tryptophan into amino acid position 162 of the MHC HLA-A2:01 class I heavy chain and by using the mouse MHC class II beta chain to form chimeric class II antigens with endogenous class II alleles. The virus encoded mismatched MHC antigen presenting molecules are expressed functionally in the LN following intradermal inoculation provoking polyclonal T cells responses. Three days later CAR T cells are generated by directly injecting retroviruses encoding CARs of interest into the responding LN. Mouse CD19-specifc CAR T cells created in this manner in B6-DQ8 and DQ8/A2 mice effectively target endogenous B cells and are therapeutic in male and female Emu-myc lymphomas demonstrating the potential for the generating functional CAR T cells directly in vivo. While in situ CAR T cells are readily produced in B6, B6-IA0/DQ8, B6-IA0/DQ8/A2, and B6-IA0/DQ6 LNs, functional differences among the strains emerged in the periphery suggesting that properties of the autoimmune-associated HLA DQ8 class II allele is particularly reactive during the production of CAR T cells in vivo. Funding Sources MustangBio, Inc Mayo Clinic Center of Biomedical Research Mayo Clinic Department of Immunology Mayo Clinic Graduate School of Biomedical Science Fraternal Order of Eagles Mayo Clinic Ventures NIH R21 AI 097337 NIH R01 CA 178804 NIH T32 AI 07425 Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
Prostate Cancer Screening Practices Among High-Risk Patients: A Retrospective Analysis
Ghosh, Aditya , Sivasubramanian, Barath P., Asif, Rana H. , Barker, Steven A. , Dirisanala, Sudha, Ghosh, Aditya K , Barker, Steven, Robinson, Shane S. , Rynarzewska, Ania Izabela , Johnson, Andrew

Mayo Clinic

American Journal of Men's Health | November 20, 2025 | Volume: 19 | Issue: 6 | Pages: No page available

10.1177/15579883251392440 | PMID 41263152 Get It

Prostate cancer is the second most common cancer in U.S. men, with higher incidence and mortality among African Americans and those with genetic or familial risk. Despite guidelines promoting early detection, prostate-specific antigen (PSA) screening in primary care remains inconsistent. We assessed PSA screening patterns and the association between risk factors and testing. A retrospective analysis was conducted on men aged ≥40 seen at primary care clinics from 2020 to 2022. Risk scores were created based on the number of prostate cancer risk factors. Univariate and multivariate analyses assessed associations between the risk scores, PSA screening, and cancer diagnosis. Of 176,326 patients, 31.4% underwent PSA testing, rising to 78.1% with a risk score of 4. The predictive model was significant (χ 2 = 19,527.021, df = 11, p < .001). PSA testing odds were higher with Medicaid or commercial insurance (vs. Medicare) and lower for self-pay patients. Former and never smokers were more likely to be tested than current smokers. Age, African American race, and family history increased the odds of receiving PSA testing. Prostate cancer diagnosis reached 25% at a risk score of 5, with significant predictors including older age, African American race, family history, and mention of “prostate” in clinical notes. PSA screening remains underused in primary care, even among high-risk patients. More risk factors were linked to higher testing rates, but African American and low-income groups were under-tested. Provider education and decision-support tools may improve guideline adherence and equity.
sEEG ‐guided responsive neurostimulation to treat neocortical epilepsy: A multicenter retrospective study of the efficacy and safety of depth electrode‐mediated neuromodulation
Sadeghzadeh, Sina , Purger, David , Bhanot, Priya , Johnson, Noriah , Schonfeld, Ethan , Abikenari, Matthew , Jain, Bhav , Aronson, Joshua P. , Drees, Cornelia , Fisher, Tiffany , Gray, Tyler E. , Ojemann, Steven , Sather, Michael D., Skidmore, Christopher , Yoo, Ji Yeoun , Graber, Kevin , Halpern, Casey H. , Buch, Vivek , Parker, Jonathon J. , Drees, Cornelia , Gray, Tyler E , Hines, Kevin , Karakis, Ioannis , Quraishi, Imran H , Raslan, Ahmed M , Wu, Chengyuan , Yoo, Ji Yeoun , Buch, Vivek , Skidmore, Christopher , Barbosa, Daniel A. N. , Huang, Yuhao , Park, Jay J. , Gerrard, Jason L. , Ghatan, Saadi , Jobst, Barbara C. , Karakis, Ioannis , Willie, Jon T , Wu, Chengyuan

Mayo Clinic

Epilepsia Open | November 18, 2025 | Volume: 11 | Issue: 1 | Pages: 146-161

10.1002/epi4.70180 | PMID 41251192 Get It

Abstract Objectives Pivotal trials have established the effectiveness of the Responsive Neurostimulation System (RNS® System) in treating focal epilepsy. In clinical trials, depth leads were primarily used to treat mesial temporal seizure onsets while cortical strip leads were used to treat neocortical seizure onsets. Here, we systematically analyze the safety and efficacy of stereoelectroencephalography (sEEG)‐guided depth leads to provide responsive stimulation to neocortical gray matter. Methods Patients were stratified as strong responders (>median cohort seizure reduction %), weak responders (>0% and ≤median cohort seizure reduction %), and anti‐responders (≤0%) based on percent seizure reduction at 1 year post‐implant (1‐Y). Pre‐operative T1‐weighted magnetic resonance imaging and post‐operative computed tomography images were merged, and the Euclidean distance between the sEEG epileptic focus (sEEG‐EF) and the nearest RNS System depth lead contacts was calculated. Results A total of 87 depth leads were implanted in 55 patients across neocortical brain regions. The median reduction in clinical seizures improved from 66.7% at 1‐Y to 77.5% at long‐term follow‐up (LTFU: 2.35 ± 0.95 years), with 10 patients (18.2%) achieving complete seizure freedom. Seven patients (12.7%) experienced six serious adverse events. At 1‐Y, shorter Euclidean distance between the sEEG‐EF and RNS System depth leads predicted improved seizure outcome in strong responders ( β = −0.84, p = 0.008) but not in weak responders ( β = 0.21, p = 0.9) or anti‐responders ( β = −20.34, p = 0.11). At LTFU, there was no significant relationship between Euclidean distance and seizure reduction in strong responders ( β = 0.77, p = 0.18), weak responders ( β = 2.05, p = 0.54), or anti‐responders ( β = 0.24, p = 0.99). Exploratory analyses at 1‐Y showed nominal associations between older age ( ρ = 0.32), longer epilepsy duration ( ρ = 0.27), and non‐mesial temporal sEEG‐EFs and greater seizure reduction; however, none survived Bonferroni correction (adjusted α = 0.0027; all post‐correction p > 0.0027), and no associations were observed at LTFU. Significance In this series, neocortical depth leads for RNS therapy had favorable safety and efficacy and proximity to the sEEG‐EF drove initial outcomes for strong responders to RNS therapy. Plain Language Summary In this multi‐center study, patients with difficult‐to‐treat seizures received brain‐responsive stimulation using a device called responsive neurostimulation (RNS), which delivers small electrical pulses to reduce seizures. We focused on patients treated with electrodes placed in the brain's outer regions (the neocortex) and guided by a mapping procedure called sEEG. On average, patients had their seizures cut by two‐thirds after one year and by more than three‐quarters with longer follow‐up, with about one in five becoming seizure‐free. The treatment was safe, and closer electrode placement to the seizure source helped explain early—but not long‐term—improvements.
Reduction versus fusion in situ for isthmic spondylolisthesis: a systematic review and meta-analysis
Johnson, Sarah E. , Nguyen, Ryan, Papisetty, Karthik, Aljanaahi, Mahani, Pennington, Zach , Bydon, Mohamad , Katsos, Konstantinos, Pennington, Zach , Nguyen, Ryan, Michalopoulos, Giorgos D. , Nathani, Karim Rizwan , Ibrahim, Sufyan , Katsos, Konstantinos

Mayo Clinic

Journal of Neurosurgery: Spine | November 17, 2025 | Volume: 44 | Issue: 1 | Pages: 62-71

10.3171/2025.4.spine241213 | PMID 41043182 Get It

OBJECTIVE Isthmic spondylolisthesis impacts up to 11.5% of the general population. For patients who have failed conservative therapy, decompression and fusion or decompression alone are options for surgical management. However, there remains debate as to whether reduction of mobile spondylolisthesis is integral to good patient outcomes. The present systematic review and meta-analysis aimed to address this by comparing clinical and radiological outcomes between patients treated with fusion in situ and those undergoing fusion with reduction of isthmic spondylolisthesis. METHODS The Scopus, EMBASE, Medline, and Cochrane databases were systematically queried on the basis of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify studies comparing treatment outcomes in patients with isthmic spondylolisthesis after in situ fusion or fusion with spondylolisthesis reduction. Endpoints of interest included Oswestry Disability Index (ODI) score, hospitalization duration, operative morbidity, and rates of surgical revision. Data from individual studies were aggregated using random-effects models to assess combined effects. RESULTS Of 277 identified studies, 7 studies were included with an aggregate 308 patients (143 underwent fusion in situ and 165 underwent reduction). Patients who underwent reduction for isthmic lumbar spondylolisthesis had significantly lower rates of pseudarthrosis at last follow-up (OR 0.22, p = 0.03). Estimated blood loss, operative time, hospitalization duration, change in ODI score, change in back pain (visual analog scale [VAS]), and reoperation rate did not differ significantly between groups. CONCLUSIONS For patients with isthmic spondylolisthesis, the present data suggest that fusion with reduction of spondylolisthesis may lower rates of pseudarthrosis as compared to in situ fusion. However, operative morbidity and improvement in patient-reported outcomes were similar between strategies.
Minimally invasive lumbar decompression versus open decompression for lumbar spinal stenosis: a propensity score–matched analysis
Chu, Tiffany , Johnson, Sarah E. , Willis, Kameron, Pennington, Zach , Graepel, Stephen , Lamer, Tim J. , Marsh, W. Richard , Chen, Selby G. , Krauss, William E. , Freedman, Brett A. , Bydon, Mohamad, Nathani, Karim R, Graepel, Stephen P, Pennington, Zach , Willis, Kameron, Nathani, Karim Rizwan , Hagedorn, Jonathan M. , Chen, Selby , Bydon, Mohamad

Mayo Clinic

Journal of Neurosurgery: Spine | November 17, 2025 | Volume: 44 | Issue: 1 | Pages: 55-61

10.3171/2025.6.spine25331 | PMID 41105977 Get It

OBJECTIVE Hundreds of thousands of Americans undergo decompression for lumbar spinal stenosis annually. The mild (minimally invasive lumbar decompression) procedure was developed as a potentially less invasive alternative to open decompression; however, much of the evidence has been gathered from industry-sponsored studies. The present study sought to compare real-world clinical outcomes between the mild procedure and open decompression for lumbar spinal stenosis. METHODS All patients who underwent the mild procedure at a single-institution, multisite, tertiary care center from 2005 to October 2024 were included. One-to-one propensity score matching was used to identify patients who underwent open decompression at the same institution, with age, sex, smoking, and comorbidities as covariates. Primary outcomes were change in pain on the numeric rating scale (NRS), surgical reoperation, and perioperative complications. For pain, the minimal clinically important difference (MCID) was defined as a 30% improvement in NRS score. RESULTS A total of 175 patients who underwent the mild procedure (mean age 76.3 ± 8.7 years; 44.6% female) were matched to 175 patients treated with open decompression (mean age 75.4 ± 8.7 years; 44.0% female). Among patients with at least 60 days of follow-up, those treated with open decompression were more likely to achieve the MCID for pain (43.1% vs 22.2%, p < 0.001). Patients treated with mild were more likely to require reoperation (46.2% vs 29.3%, p = 0.008). Those who underwent the mild procedure experienced lower rates of durotomies (0% vs 2.9%, p = 0.024) but had higher rates of neurological deficits (6.3% vs 0.6%, p = 0.003). CONCLUSIONS For patients with symptomatic lumbar stenosis, those who underwent open decompression were more likely to achieve pain improvement and less likely to require reoperation compared with those who underwent the mild procedure.
Barriers and Opportunities for Resilience Programs in IBD: Insights From the SMART Project
Chedid, Victor , Schoenoff, Shayla, Webb, Abby, English, Alana, Chedid, Victor G , Schoenoff, Shayla, English, Alana

Mayo Clinic

Inflammatory Bowel Diseases | November 14, 2025 | Volume: 32 | Issue: 1 | Pages: 196-197

10.1093/ibd/izaf256 | PMID 41236826 Get It

Meniscal Repair in the Setting of Revision Anterior Cruciate Ligament Reconstruction: 6-Year Follow-up Results From the MARS Cohort
Group;, MARS, Fox, Jake A. , Huston, Laura J. , Haas, Amanda K. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Amendola, Annunziato , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M. , Creighton, R. Alexander , Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C., Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCormack, Robert G. , Miller, Bruce S., Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Shea, Kevin G. , Slauterbeck, James R., Smith, Matthew V. , Svoboda, Col. Steven J., Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Williams, James S., Wolcott, Michelle L., York, James J. , Wright, Rick W. , Svoboda, Steven J. , Group;, MARS, Pennings, Jacquelyn S. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J., Brophy, Robert H. , Carpenter, James E., Cox, Charles L. , David, Tal S. , Flanigan, David C. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Kaeding, Christopher C. , Marx, Robert G. , McAllister, David R. , McCarty, Eric C. , Miller, Bruce S., Owens, Brett D. , Sherman, Orrin H. , Spang, Jeffrey T. , Vidal, Armando F. , Wolf, Brian R.

Mayo Clinic

The American Journal of Sports Medicine | November 12, 2025 | Volume: 53 | Issue: 14 | Pages: 3435-3445

10.1177/03635465251387333 | PMID 41220248 Get It

Background: Meniscal preservation has been demonstrated to contribute to long-term knee health and has been a successful intervention in isolation and in patients with anterior cruciate ligament reconstruction (ACLR). The long-term results of meniscal repair in the setting of revision ACLR have yet to be documented. Purpose: To report the incidence of meniscal repair failures at the 6-year follow-up in a cohort of patients who underwent concurrent revision ACLR and primary meniscal repair. Study Design: Prospective cohort study; Level of evidence, 2. Methods: All revision ACLRs with concomitant primary meniscal repair cases from a multicenter group between 2006 and 2011 were selected. Six-year follow-up was obtained to determine whether any subsequent surgery had occurred since their initial revision ACLR. If so, operative reports were obtained, whenever possible, to verify pathological condition and treatment. Results: In total, 221 patients from 1234 revision ACLRs underwent concurrent primary meniscal repairs (18% of the cohort). There were 238 repairs performed: 173 medial and 65 lateral. The majority of these repairs (n = 181; 76%) were performed with an all-inside technique. Six-year surgical follow-up was obtained in 77% (171/221) of the cohort, or 189 of 238 (79%) of the repairs (136 medial, 53 lateral). The meniscal repair failure rate, defined as reoperation, was 16% (31/189) at 6 years. Of the 31 failures, 28 were medial (24 all-inside, 4 inside-out; 28/136 = 20.6% failure rate) and 3 were lateral (2 all-inside, 1 inside-out; 3/53 = 5.7% failure rate). Three medial failures were treated in conjunction with a subsequent repeat revision ACLR. Medial tears underwent reoperation for failure at a significantly higher rate than lateral tears (20.6% vs 5.7%; P = .01) and had a significantly shorter survival time compared with lateral tears ( P = .02). No difference was found between the failure and nonfailure groups when it came to tear type, tear length, repair technique utilized, suture/implant type, or number of sutures used between the 2 groups. Conclusion: Meniscal repair in the revision ACLR setting has a 16% failure rate at 6 years. Failure rates for medial tears (20.6%) were found to be higher than that for lateral tears (5.7%), which aligns with previous studies in both the revision and primary ACLR setting.
Three‐dimensional surface scanning of patients to extend computed tomography field of view and scan length for dose calculation and collision avoidance in radiotherapy treatment planning
Jackson, Amanda, Shrestha, Deepak K. , Johnson, Perry , Jackson, Amanda M

Mayo Clinic

Journal of Applied Clinical Medical Physics | November 11, 2025 | Volume: 26 | Issue: 11 | Pages: No page available

10.1002/acm2.70333 | PMID 41215563 Get It

Abstract Background Radiotherapy treatment planning requires knowledge of a patient's anatomical surface for use in dose calculations, collision checks, or surface‐guided radiation therapy (SGRT). This information is usually obtained from a computed tomography (CT) scan which may encounter field‐of‐view (FOV) limitations or require additional radiation dose beyond the treatment area to capture the full patient habitus. Purpose This study demonstrates an affordable alternative solution to obtain a patient's surface information without CT or room mounted surface‐guidance imaging cameras for the purpose of detecting patient collisions and providing additional skin surface information needed for appropriate depth calculations of clipped FOV scans. Methods Three‐dimensional (3D) surface models of five patients were acquired immediately prior to CT simulation using an iPad Air 2 equipped with a Structure Sensor Pro and Monocle SS application. The 3D surfaces were manually registered to the CT images and nearest distances between CT surface and 3D surface were calculated. Nearest distance calculations were also performed with a 2 mm CT rind structure that excluded select regions not relevant to surface detection. To demonstrate the advantage of having additional scan length for clearance checks, a collision simulated plan was evaluated with a shortened CT scan length versus with additional 3D surface information. Results CT rind to 3D scan surface mean distances for each patient were 1.65 mm, 0.99 mm, −0.93 mm, −0.79 mm, and −1.53 mm with standard deviations of 6.51 mm, 6.71 mm, 3.38 mm, 2.84 mm, and 2.69 mm. Conclusion This study demonstrates the feasibility of an accessible low‐cost 3D surface scanning solution to supplement clipped field‐of‐view CT scans and reduce CT scan lengths by obtaining important patient surface data for improved calculation accuracy, treatment clearance checks, and SGRT.
TIP-11. MOMENTUM-1: a multicenter, randomized, open-label, phase 2 study of [177Lu]Lu-DOTA-TATE in adults with progressive grade 1-3 meningioma (RTOG 3523)
Kurz, Sylvia C. , Rabbee, Nusrat, Wen, Patrick Y. , Kalapurakal, John A. , Bi, Lingge, Ivanidze, Jana , Cahill, Jennifer, Wen, Patrick Yung , Peereboom, David M. , Huang, Raymond Y. , Perry, Arie , Cahill, Jennifer, Johnson, Derek R. , Mehta, Minesh P. , Sulman, Erik P.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v422-v422

10.1093/neuonc/noaf201.1671 Get It

Abstract BACKGROUND While most meningiomas are classified as low-grade tumors with indolent behavior, a subset is characterized by a more aggressive clinical course and patients undergo repeated resections and courses of radiation. Once these therapies fail, prognosis is poor and progression-free survival (PFS) rates at 6 months (PFS-6) are estimated to only be 43.6% for WHO grade 1 and 38% for WHO grade 2/3 meningiomas. Effective medical therapies are limited. Somatostatin receptor 2 (SSTR2) is expressed in a majority of meningiomas and represents a suitable treatment target. [177Lu]Lu-DOTA-TATE (177Lu-Dotatate) is an SSTR2-targeted radioligand therapy, established as standard of care in the treatment of certain neuroendocrine tumors. Two ongoing non-randomized studies of 177Lu-Dotatate in meningiomas have reported encouraging efficacy compared to historical benchmarks. METHODS/STUDY DESIGN The MOMENTUM-1 study (RTOG 3523, NCT#06955169) is a multicenter, randomized, open-label study of 177Lu-Dotatate in adult patients with progressive intracranial WHO grade 1-3 meningiomas. Up to 130 eligible subjects are randomized in a 2:1 fashion to 177Lu-Dotatate at 7.4 GBq (200 mCi) every 4 weeks for 4 (+2 optional) doses or standard of care (SOC) medical therapy as defined by the protocol and deemed appropriate by the local investigator. Treatment responses are assessed by gadolinium-enhanced MRI brain and [68Ga]Ga-DOTA-TATE (68Ga-Dotatate) PET imaging. At time of progression, cross-over from the SOC to the interventional treatment arm is allowed. The primary endpoint is PFS. Secondary endpoints include PFS-6, OS-12, OS, response assessments (ORR, DCR), safety/tolerability, and patient-reported outcomes. RESULTS/CONCLUSION MOMENTUM-1 is a multicenter, randomized, open-label, phase II study of 177Lu-Dotatate in adult patients with progressive WHO grade 1-3 meningioma. This clinical trial is expected to start enrolling patients in the United States in the third quarter of 2025. Details on study design, eligibility criteria for subject enrollment and study site eligibility criteria will be presented.